| Company/Division name | UC Davis Alpha Stem Cell Clinic |
| Parent company | UC Davis |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2022 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 8 |
| State(s) reshored to: | CA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals, Medical Equipment & Supplies, Stem cell and gene therapy, clinical trials |
| Product(s) reshored | stem cell |
| What domestic positive factors made reshoring more attractive? | Government Incentives, Proximity to customers/market, Skilled workforce availability/training |
